I think Charter never intended to distribute DR-70 as a blood test. I think he just wanted a way to buy kits that he could then use for his Saliva Test. UNI has the rights to sell onko-sure but Charter never intended to sell onko-sure, IMO.
The way I see it: in 2003 Charter had his idea about the Saliva test so he signed an agreement with AMDL to get the resource of buying kits (much cheaper than buying individual tests - at $400 per kit, that's about $4 per test).
The timeline then gets fuzzy but the wiki says that Charter did his "clinical trials" between 2003 and 2012. Makes sense that he would have to renew his Radient agreement at some point (2010 seems to fit) -- Maybe he ran out of tests in 2010 or they went bad on the shelf.
I don't think Charter wants to sell a test. I think he wants to sell a business named "Cancer Screen Technologies." The problem is, the buyer would want to see the scientific data behind the "Clinical Trials." How will he get around that troublesome detail?
I also don't understand why they abandoned the Australian Patent Application for DR-70. Maybe because Australia doesn't matter to anyone since "Cancer Screen Technologies" is in Hong Kong.
News 
Market Data 
Discover 
